ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Trifluridine

Also written as “Suvemcitug injection, trifluridine/tipiracil tablets”.

Its studies are mostly in Colorectal Neoplasms · Mycobacterium avium-intracellulare Infection, led by 3 companies.

Drug pageTrifluridine: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 2, 19993 company-led studies, 1 open or runningNext primary completion: Jan 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only10 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
Otsuka10 open or runningphase 1since May 24, 2013May 24, 2013none ahead
Simcere Pharmaceutical Groupits history only11 open or runningphase 3since Sep 30, 2025Sep 30, 2025Jan 2028phase 3 · NCT07361003

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Otsuka only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 24, 2013First study: phase 1 study in Advanced Solid TumorsFirst studyNCT01867866 · 44 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DNA inhibitor”ChEMBL 37, by rule

Studies

The one study Otsuka leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01867866Advanced Solid Tumors · United States1CompletedOct 201344

How it is read

Names in the registry

  • “Trifluridine”, 2 entries
  • “Suvemcitug injection, trifluridine/tipiracil tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.